A Multicenter, Vehicle-controlled, Double-Masked, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
Latest Information Update: 22 Mar 2023
At a glance
- Drugs AGN 231868 (Primary) ; Vimirogant (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie; Allergan
- 25 Mar 2022 Status changed from active, no longer recruiting to completed.
- 14 Feb 2022 Planned End Date changed from 2 Feb 2022 to 15 Mar 2022.
- 14 Feb 2022 Planned primary completion date changed from 2 Feb 2022 to 15 Mar 2022.